Germany and India are collaborating on various projects to prevent infectious diseases. The two countries are also aiming at finding ways to cope with and reduce the risks of biological warfare.
See on www.dw.de
HARBIN, Feb 28 (Bernama) — National approval has been granted to turn the site of Japan’s notorious Unit 731 in northeast China’s Harbin into a cultural park, Xinhua news agency reported.
The park will be built upon the ruins of Unit 731 and will exhibit artifacts of biological and chemical warfare, said a source with the Exhibition Hall of Crime Evidence of Japanese Germ Factory in Heilongjiang province’s capital Harbin.
See on www.bernama.com
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ — Menon Biosensors M2 Technology Demonstrates Wide Dynamic Range for Pathogen Detection and Quantification. M2 technology expands applications through massive increase in quantification with sample to answer in less than one hour.
See on www.prnewswire.com
It beat humans at Jeopardy! and cancer
diagnostics. Imagine what it could do if it went mobile.
This is exactly what IBM wants to see happen with its Watson
supercomputer, and sooner rather than later.
And…Ascel Bio and the National Infectious Disease Forecasting Center.
See on www.wired.co.uk
Fetchez la vache! Non-native (or invasive) forms of animal
species could be used as a new biological weapon. “The invasive can
be used to destroy crop yields of major food crops — wheat, for
example — or lumber commodities, or farm animals.
See on www.wired.co.uk
Viruses in UAE to be tracked by satellite to prevent outbreaks Zawya (registration) “The increase in prevalence of many infectious diseases together with the on-going evolution of viral and microbial variants, and selection for drug resistance,…
See on news.google.com
The objective of this RFI is to identify candidate Small organic Molecules Inhibitors (SMI) that have the potential to potently and specifically inhibit multiple drug resistance (MDR) bacterial pathogens including tier-1 CDC/DoD listed bacteria.
The DoD is interested in exploring availability of SMIs that possess new mechanism of action(s) and are bactericidal against broad MDR bacterial infectious pathogens. DoD welcomes engagement of all sources that have reached at an advanced Phase I clinical studies or completed this clinical Phase.
See on www.fbo.gov